Biotech Values

[rkrw]

I certainly don't know of any generic drug company's sub $250M enterprise value that have better prospects. As far as branded drug/biotech plays, it would all be speculative. If there's any lesson on MNTA, I think it's that they need a first to market, biogeneric, no potential competition to speak of. Then the cash flow would be insane year after year.